Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Company Drug

Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension

Fineline Cube May 28, 2025

China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval...

Company Deals

Jiangsu Nhwa’s Investee Jiangsu Haoxinqing Plans Overseas Listing

Fineline Cube May 28, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced that its investee company Jiangsu Haoxinqing...

Company Deals

Shenyang Xingqi Pharmaceuticals Plans Private Placement to Fund R&D Center

Fineline Cube May 28, 2025

China-based Shenyang Xingqi Pharmaceutical Co., Ltd (SHE: 300573) announced plans for a private placement of...

Company Drug

Novartis’ Beovu Approved by NMPA for Diabetic Macular Edema Treatment

Fineline Cube May 28, 2025

Swiss giant Novartis’ (NYSE: NVS) Beovu (brolucizumab) received approval from China’s National Medical Products Administration...

Company Drug

Mabworks’ MIL62 Gains NMPA Review for NMOSD Treatment

Fineline Cube May 28, 2025

China-based Beijing Mabworks Biotech Co., Ltd announced that its New Drug Application (NDA) for MIL62,...

Company Deals

EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager

Fineline Cube May 28, 2025

Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a...

Company Deals Drug

Eli Lilly to Acquire SiteOne Therapeutics for Up to USD 1 Billion

Fineline Cube May 28, 2025

US-based pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced plans to acquire compatriot biotech...

Company Drug

Junshi Biosciences’ Junshida Wins NMPA Approval for HeFH and Statin-Intolerant Patients

Fineline Cube May 28, 2025

China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Sino Biopharmaceutical Presents TQB2102 Phase I Results at ASCO 2025

Fineline Cube May 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented preliminary results from a Phase I clinical study...

Company

BeiGene Rebrands to BeOne Medicines and Relocates to Switzerland

Fineline Cube May 28, 2025

BeiGene (NASDAQ: ONC, HKG: 6160, SHA: 688235), a global oncology company, has officially rebranded to...

Company Deals Drug

Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize

Fineline Cube May 28, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....

Company Medical Device

China’s NMPA Approves Lifetech’s Aortic Fenestration Stent System

Fineline Cube May 28, 2025

China’s National Medical Products Administration (NMPA) recently approved an innovative aortic in-situ fenestration branch reconstruction...

Company Drug

Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study

Fineline Cube May 28, 2025

Sino-US biotech Phanes Therapeutics Inc. announced the first patient dosing in a clinical study for...

Company Drug

StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment

Fineline Cube May 27, 2025

Hefei-based gene therapy biotech StarryGene announced the initiation of a Phase II clinical study for...

Company Deals

Sinotau Pharma Files for HK IPO Focused on Radiopharmaceutical Pipeline

Fineline Cube May 27, 2025

China-based Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a leader in nuclear medicine (radiopharmaceuticals), announced...

Company Deals

Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC

Fineline Cube May 27, 2025

Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...

Company Drug

Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment

Fineline Cube May 27, 2025

Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...

Company Deals

Harbin Gloria Partners with Kowa Pharmaceuticals to Promote Parmodia in China

Fineline Cube May 27, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) announced last week that it has entered...

Company Drug

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients

Fineline Cube May 27, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology company proposing to rename...

Company Deals

Ayshealth Technology Secures Angel Funding for Artificial Blood Vessel Research

Fineline Cube May 27, 2025

Guangzhou-based Ayshealth Technology, a developer of tissue repair and reconstruction devices, has reportedly secured an...

Posts pagination

1 … 180 181 182 … 692

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
  • OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.